ME Therapeutics is focused on developing innovative cancer therapeutics that specifically target myeloid cells, a class of immune cells that can suppress the body’s anti-tumor immune response. Their approach aims to enhance the effectiveness of existing immuno-oncology (IO) treatments, such as checkpoint inhibitors, which have shown success in treating certain cancers but leave many patients without effective options. The company is advancing two main drug development programs: one involves an anti-G-CSF antibody candidate designed to block a cytokine that promotes immune suppression, while the other includes myeloid-targeted prodrug candidates that utilize lipid nanoparticles to deliver active drugs directly to tumor sites, thereby overcoming the suppressive effects of myeloid cells.

In addition to these development programs, ME Therapeutics is also engaged in a drug discovery initiative aimed at creating novel lipid nanoparticle formulations for effective delivery of small molecules and nucleic acids to myeloid cells within tumors. This multifaceted approach not only seeks to improve the response rates of current IO therapies but also aims to address the significant unmet needs in cancer treatment by potentially allowing a broader range of patients to benefit from immunotherapy. By targeting the pathways of myeloid cell biology that are currently underexplored, ME Therapeutics is positioning itself at the forefront of the next wave of cancer immunotherapy advancements.

Canada

ME Therapeutics is a Biotechnology company that specializes in Immuno Oncology, focusing on treating previously untreatable cancers by targeting the immune system.

ME Therapeutics

Company Details